Candito M, Thyss A, Albertini M, Deville A, Politano S, Mariani R, Chambon P
Laboratoire de Biochimie, Hôpital Pasteur, Nice, France.
Med Pediatr Oncol. 1992;20(3):215-20. doi: 10.1002/mpo.2950200306.
Assays of urinary catecholamines and their metabolites (HVA, VMA, dopamine) permit biochemical diagnosis of neuroblastoma in approximately 80% of patients. The urinary methylated catecholamine metabolites normetanephrine (NMN), metanephrine (MN), and 3-methoxytyramine (3-MT) were analyzed in 18 patients with neuroblastoma and compared with reference values established for 69 healthy pediatric controls. All 18 neuroblastoma patients had raised urinary excretion of at least one of the three commonly assayed metabolites (HVA, VMA, dopamine). Similarly, raised urinary excretion of a methylated metabolite was noted in all but one of the neuroblastoma patients. The 3-MT level was pathologic in 16 of the 18 patients (89%). In this series, 3-MT assay sensitivity was sufficient to warrant trials on a larger population including comparison with patients considered nonsecretors by routine assay procedures.
对尿儿茶酚胺及其代谢产物（高香草酸、香草扁桃酸、多巴胺）进行检测，可对约80%的神经母细胞瘤患者做出生化诊断。对18例神经母细胞瘤患者的尿甲基化儿茶酚胺代谢产物去甲变肾上腺素（NMN）、变肾上腺素（MN）和3-甲氧基酪胺（3-MT）进行了分析，并与69例健康儿童对照者所确立的参考值进行比较。18例神经母细胞瘤患者中，所有患者的尿中至少有一种常用检测代谢产物（高香草酸、香草扁桃酸、多巴胺）的排泄量升高。同样，除1例神经母细胞瘤患者外，其他患者均发现尿甲基化代谢产物排泄量升高。18例患者中有16例（89%）的3-MT水平呈病理性。在该系列研究中，3-MT检测的敏感性足以保证在更大规模人群中进行试验，包括与通过常规检测程序被视为无分泌功能的患者进行比较。
